Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
11.05
-1.14 (-9.35%)
At close: Jan 2, 2026, 4:00 PM EST
11.07
+0.02 (0.18%)
After-hours: Jan 2, 2026, 5:23 PM EST
Tenax Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Tenax Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $22.5, which forecasts a 103.62% increase in the stock price over the next year. The lowest target is $20 and the highest is $25.
Price Target: $22.5 (+103.62%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tenax Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 3 | 3 | 3 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $14 → $25 | Strong Buy | Maintains | $14 → $25 | +126.24% | Dec 17, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $20 | Buy | Initiates | $20 | +81.00% | Sep 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +26.70% | Aug 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $16 | Buy | Initiates | $16 | +44.80% | Oct 24, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +44.80% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.40
from -1.15
EPS Next Year
-1.60
from -1.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.43 | -1.50 | ||||
| Avg | -1.40 | -1.60 | ||||
| Low | -1.36 | -1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.